Our top pick for
NN, Inc is a conglomerates business based in the US. NN shares (NNBR) are listed on the NASDAQ and all prices are listed in US Dollars. NN employs 5,418 staff and has a trailing 12-month revenue of around USD$777.1 million.
|52-week range||USD$1.345 - USD$7.35|
|50-day moving average||USD$6.6076|
|200-day moving average||USD$6.0778|
|Wall St. target price||USD$9|
|Dividend yield||USD$0 (0%)|
|Earnings per share (TTM)||USD$-6.673|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing NN stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NN's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
NN's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.93. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NN's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
NN's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$94.7 million.
The EBITDA is a measure of a NN's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$777.1 million|
|Operating margin TTM||0.3%|
|Gross profit TTM||USD$205.8 million|
|Return on assets TTM||0.1%|
|Return on equity TTM||-54.57%|
|Market capitalisation||USD$292.7 million|
TTM: trailing 12 months
There are currently 1.5 million NN shares held short by investors – that's known as NN's "short interest". This figure is 0.9% down from 1.5 million last month.
There are a few different ways that this level of interest in shorting NN shares can be evaluated.
NN's "short interest ratio" (SIR) is the quantity of NN shares currently shorted divided by the average quantity of NN shares traded daily (recently around 132555.56544969). NN's SIR currently stands at 11.23. In other words for every 100,000 NN shares traded daily on the market, roughly 11230 shares are currently held short.
However NN's short interest can also be evaluated against the total number of NN shares, or, against the total number of tradable NN shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NN's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 NN shares in existence, roughly 30 shares are currently held short) or 0.0423% of the tradable shares (for every 100,000 tradable NN shares, roughly 42 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against NN.
Find out more about how you can short NN stock.
We're not expecting NN to pay a dividend over the next 12 months.
NN's shares were split on a 3:2 basis on 6 December 1995. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your NN shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for NN shares which in turn could have impacted NN's share price.
Over the last 12 months, NN's shares have ranged in value from as little as $1.345 up to $7.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NN's is 3.342. This would suggest that NN's shares are significantly more volatile than the average for this exchange and represent a higher risk.
NN, Inc., a diversified industrial company, designs and manufactures high-precision solutions, components, and assemblies for the medical, aerospace and defense, electrical, automotive, and general industrial markets. It operates through Life Sciences, Mobile Solutions, and Power Solutions segments. The Life Sciences segment designs and manufactures a range of high-precision metal and plastic components, assemblies, and finished devices, such as surgical knives, bioresorbable implants, surgical staples, cases and trays, orthopaedic implants and tools, laparoscopic devices, and drug delivery devices for the orthopaedics and medical/surgical end markets. The Mobile Solutions segment manufactures system critical components for fuel systems, engines and transmissions, power steering systems, and electromechanical motors for general industrial and automotive end markets. The Power Solutions segment designs and manufactures a range of high-precision metal and plastic components, assemblies, and finished devices used in applications ranging from power control to flight control and for military devices. Its products include electrical contacts, connectors, contact assemblies, and precision stampings for the electrical end market; and high precision products for the aerospace and defense end markets. The company sells its products worldwide primarily to manufacturers directly. NN, Inc. was founded in 1980 and is headquartered in Charlotte, North Carolina.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.